Handelsavisen
prelaunch
40
405920.KQ KOSDAQ Food Retail & Distribution

405920.Kq

$2 040,00
Open in Charts → Attach watcher ⌖
KRW
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
26,2B KRW
P/E
EV / Rev
Div yield
0,00 %
Op margin
1,3 %
ROE
0,1 %
Net margin
0,1 %
Debt / equity
0,56
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the Food & Drug Retailing industry, generating revenue primarily through the sale of food and drug products to consumers.

Business. The company operates in the Food & Drug Retailing industry, generating revenue primarily through the sale of food and drug products to consumers.

Classification92 %
SectorConsumer Non-Cyclicals
Business sectorFood & Drug Retailing
IndustryFood Retail & Distribution
ActivityFood & Drug Retailing
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
0,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 405920.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 405920.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the Food & Drug Retailing industry, generating revenue primarily through the sale of food and drug products to consumers.

    Classification92 %
    SectorConsumer Non-Cyclicals
    Business sectorFood & Drug Retailing
    IndustryFood Retail & Distribution
    ActivityFood & Drug Retailing
    AI synthesis
    GENERATED

    The company maintains a market price of 2415.0 KRW per share, with a market capitalization of 30,990,229,095 KRW. Its price-to-earnings ratio is 364.58, significantly higher than the typical range for the industry, indicating a high valuation relative to earnings. The price-to-book ratio is 0.48, suggesting that the company is trading at a discount to its book value. The enterprise value to EBITDA ratio is 58.89, and the enterprise value to revenue ratio is 0.75, both of which are key metrics for assessing valuation in the retail sector.

    Profitability metrics show a return on equity of 0.0013 and a return on assets of 0.0007, both of which are below the industry median, indicating weak returns relative to equity and asset base. The company's operating income is 1,053,736,940 KRW, with a gross profit of 36,227,240,090 KRW, but the net income is only 85,003,410 KRW, reflecting high operating and non-operating expenses. The company's debt-to-equity ratio is 0.56, which is relatively moderate, but the current ratio of 1.57 suggests that the company has sufficient short-term assets to cover its short-term liabilities.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the risk of revenue volatility due to regional economic or regulatory changes. The company's capital structure includes 36,318,449,440 KRW in long-term debt and 5,257,181,350 KRW in cash and equivalents, resulting in a net cash position that is negative after subtracting total debt.

    The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent fiscal year. The capital expenditure of -4,084,239,150 KRW indicates a reduction in investment in physical assets, which may signal a strategic shift or financial constraints. The free cash flow is negative at -468,598,100 KRW, suggesting that the company is not generating enough cash from operations to cover its capital expenditures.

    The company faces moderate liquidity risk, as indicated by the risk assessment, and low dilution risk. However, the negative net cash position after subtracting total debt is a key flag that could impact the company's ability to meet short-term obligations. The risk assessment also highlights the need for close monitoring of the company's liquidity position.

    Recent events, including the latest financial filing, show a decline in profitability and a reduction in capital expenditures. The company's operating cash flow is 6,865,617,500 KRW, which is positive but not sufficient to cover the capital expenditures. The company's financial health is further complicated by the high price-to-earnings ratio and low return on equity, which may deter investors seeking strong returns.

    Key takeaways
    • The company is trading at a high price-to-earnings ratio, indicating a premium valuation relative to earnings.
    • The company's return on equity and return on assets are below the industry median, suggesting weak profitability.
    • The company has a moderate debt-to-equity ratio but a negative net cash position after subtracting total debt.
    • The company's free cash flow is negative, indicating that it is not generating enough cash from operations to cover its capital expenditures.
    • The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent fiscal year.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $2 040,00
    Market cap
    $30.99B
    Enterprise value
    $62.05B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    9.0x
    P / B
    0.5x
    P / Tangible book
    0.5x
    Tangible book
    $64.92B
    Net cash
    -$31.06B
    Current ratio
    1.6
    Debt / equity
    0.6
    ROA
    0.1%
    ROE
    0.1%
    Cash conversion
    8077.0%
    CapEx / revenue
    -5.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin1,3 %Below median
    Net Margin0,1 %Bottom quartile
    ROE0,1 %Bottom quartile
    Capex / Rev-5,0 %Bottom quartile
    D/E0,56Below median
    Cash Conv80,77Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • 405920.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    405920.KQCanonical
    KOSDAQ · KRW

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage